Immunovia Sets Exercise Price for Series TO 3 Warrants
Immunovia Announces Exercise Price for Warrants Series TO 3
Immunovia AB (publ), a prominent player in the diagnostic industry, has announced a significant development regarding its warrants series TO 3. The exercise price for these warrants has been firmly set at SEK 0.24. This exercise period will begin on April 1, 2025, and will continue until April 15, 2025. Investors should take note that the last day for trading these warrants will be on April 11, 2025.
Insights into the Rights Issue
In the previous period, Immunovia successfully carried out a rights issue that was executed between August and September 2024. Each unit generated in this Rights Issue was composed of two shares, along with two warrants from series TO 2, and one warrant from series TO 3. It is vital for current holders to understand that each TO 3 warrant authorizes the holder to subscribe for a new share of the company. Should all existing warrants be exercised, the total anticipated funds to be raised for Immunovia will approximate SEK 14.9 million, before covering issue costs.
Key Dates and Instructions for Exercising Warrants
For warrant holders eager to subscribe for shares, they must provide notice of their intention to exercise by April 15, 2025. It is critical to note that any warrants not exercised by this deadline will expire without any value. Those who prefer not to participate in the exercise have the option to sell their warrants up until the trading deadline.
Exercising Nominee-Registered Warrants
For those with nominee-registered warrants—such as holdings within securities custody services, investment savings accounts, or endowment insurances—it is essential to inform your nominee of your intention to exercise. This process should be completed ahead of the April 15 deadline as various nominees operate on different processing schedules.
Exercising Directly Registered Warrants
Holders with directly registered warrants must fill out and submit an application form for exercising their warrants directly to the issuing agent, Vator Securities AB. As with nominee registrations, this must also be completed by April 15, 2025.
Market Activity and Trading Information
In instances where warrant holders decide against exercising, they are encouraged to trade their warrants on Nasdaq Stockholm until the deadline. The TO 3 warrants are designated under the short name IMMNOV TO 3, with an ISIN code of SE0022600102. If not exercised by the set deadline, these warrants will also expire.
Share Capital and Future Prospects
In the event that all 62,211,989 warrants series TO 3 are fully exercised, Immunovia anticipates an increase in its share capital up to SEK 9,723,625.56. This increase would facilitate the issuance of up to 62,211,989 new shares, elevating the total number of shares in circulation from 261,908,863 to 324,120,852. Consequently, the dilution effect from the full exercise of these warrants is projected to be around 19.2 percent.
Information on Complete Terms and Conditions
For those interested, complete terms and conditions regarding the warrants are accessible on the company's official website. It's vital for all participants to stay informed on specifics surrounding this exercise opportunity.
About Immunovia AB
Immunovia AB is dedicated to enhancing survival rates for pancreatic cancer patients by focusing on early detection methods. The company develops and commercializes blood-based tests that facilitate the identification of proteins and antibodies linked with high-risk individuals for pancreatic cancer. Immunovia actively collaborates with healthcare institutions, specialists, and patient advocacy groups to ensure its diagnostic tests reach those who might benefit most.
Market Potential
The United States stands as the largest market for pancreatic cancer detection. Immunovia's research indicates that approximately 1.8 million individuals in this market are at high risk for pancreatic cancer and could significantly benefit from annual surveillance testing.
Frequently Asked Questions
What is the exercise price for warrants series TO 3?
The exercise price has been determined at SEK 0.24.
When does the exercise period for the warrants begin and end?
The exercise period starts on April 1, 2025, and ends on April 15, 2025.
What happens to unexercised warrants?
Any warrants not exercised by April 15, 2025, will expire without value.
How can I exercise my warrants?
Warrant holders must notify their nominee or submit an application to the issuing agent, depending on how the warrants are registered.
What is the expected dilution if all warrants are exercised?
The expected dilution amounts to approximately 19.2 percent upon full exercise of the warrants.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
